PIPA524964

HVCN1 Polyclonal Antibody, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIPA524964-Each-of-1 In Stock ₹ 48,816.50

PIPA524964 - Each of 1

₹ 48,816.50

In Stock

Quantity

1

Base Price: ₹ 48,816.50

GST (18%): ₹ 8,786.97

Total Price: ₹ 57,603.47

Antigen

HVCN1

Classification

Polyclonal

Conjugate

Unconjugated

Gene

HVCN1

Gene Alias

0610039P13Rik; AI450555; BTS; HV1; Hvcn1; hydrogen voltage gated channel 1; hydrogen voltage-gated channel 1; mVSOP; RGD1310788; UNQ578/PRO1140; Voltage sensor domain-only protein; voltage-gated hydrogen channel 1; Vsop; Vsop.

Host Species

Rabbit

Purification Method

Antigen affinity chromatography, Protein A

Regulatory Status

RUO

Gene ID (Entrez)

84329

Content And Storage

-20° C, Avoid Freeze/Thaw Cycles

Form

Liquid

Applications

Flow Cytometry, Western Blot

Concentration

0.5 mg/mL

Formulation

PBS with 0.09% sodium azide

Gene Accession No.

Q96D96

Gene Symbols

HVCN1

Immunogen

KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human HVCN1

Quantity

400 μL

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG

Related Products

Img

Thermo Scientific

PIPA526314

--

Img

Thermo Scientific

PIPA526830

--

Img

Thermo Scientific

PIPA524908

--

Img

Thermo Scientific

PIPA525141

--

Img

Thermo Scientific

PIPA525171

--

Img

Thermo Scientific

PIPA524873

--

Img

Thermo Scientific

PIPA525475

--

Img

Thermo Scientific

PIPA526834

--

Description

  • HVCN1 (hydrogen voltage-gated channel 1), a voltage gated proton channel protein that is highly expressed in immune tissues, mediates the proton conductances required by phagocytic leukocytes for the oxidative burst that underlies microbial killing
  • HVCN1 moderates the voltage-dependent proton permeability of excitable membranes by allowing the flow of protons in accordance to their electrochemical gradient
  • HVCN1 is sensitive to zinc ions, and can be inhibited by them
  • HVCN1 may represent a new therapeutic target for B cell malignancies on continued signaling via the B cell antigen receptor.